|
|
Quark Biotech Inc. (QBI)
Sector: Pharmaceuticals
Sub-Sector: Drug Discovery
Medical Field: General Health
Est.: 1994
Stage: Clinical
http://www.quarkbiotech.com
| Quark Biotech is pioneering Endpoint Driven Drug Development (ED3). ED3 is a vertically integrated drug development approach that starts with defining a desired clinical endpoint in any specified disease to design drug candidates to achieve the defined endpoint. Quark's approach uncovers the critical gene and protein functions affecting relevant disease pathways allowing the company to develop conceptually novel drugs that provide benefits to patients. The company currently focuses on developing therapeutics to treat metabolic disorders, cancer, and renal diseases in parallel to the ongoing pharmaceutical collaborations in other disease areas.
|
|
|
